- Home
- CNEY vs ABP Comparison
CNEY vs ABP Comparison
Compare CNEY & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | ABP |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 12.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNEY | ABP |
|---|---|---|
| Price | $0.62 | $4.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 123.2K | 18.2K |
| Earning Date | 02-18-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,049,275.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $0.51 | $3.78 |
| 52 Week High | $12.23 | $60.15 |
Technical Indicators
Market Signals| Indicator | CNEY | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 30.09 | 36.74 |
| Support Level | $0.51 | $3.96 |
| Resistance Level | $0.62 | $5.08 |
| Average True Range (ATR) | 0.07 | 0.41 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 40.32 | 17.33 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.